This article has been corrected: The correct figures are given below:
The authors declare that these corrections do not change the results or conclusions of this paper.
Figure 2. Implication of Nox1 in oxaliplatin-induced ROS production and cytotoxicity.
(D). Transfected cells were also seeded in white 96-well plates to perform lucigenin assays.
Figure 3. Study of calpain expression, activity and implication in oxaliplatin-induced cytotoxicity.
(C). The transfected cells were also seeded to perform 72-hour cytotoxicity assays (C). Asteriks indicate a statistical significance with p<0.05.
Figure 7. Implication of p38 in the resistance to oxaliplatin.
(B to D). Cytotoxicity assays were performed with HT29-D4, Rox1 and Rox2 treated with oxaliplatin and incubated in the absence (Control) or in the presence of SB203580, a specific inhibitor of p38 (5 μM).
Original article: Oncotarget. 2017; 8:103710-103730. https://doi.org/10.18632/oncotarget.21780